InMed Pharmaceuticals Inc.: Deep Track Capital, LP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Deep Track Capital, LP disclosed a stake exceeding 5% in InMed Pharmaceuticals Inc. via a Schedule 13G filing with the SEC (accession 0001172661-26-005030). The filing signals a new or expanded institutional position in the small-cap biopharmaceutical company, which develops cannabinoid-based therapeutics. The exact share count and percentage were not specified in the headline disclosure. Investors will watch for further detail in the full filing and any subsequent 13G amendments that clarify whether the position is passive or active.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
InMed Pharmaceuticals Inc., Deep Track Capital, LP